ENDRA Life Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ENDRA Life Sciences generated cash of -$9,548,775, which is more than the previous year. Cash used in financing activities reached the amount of $7,518,305 last year. Net change in cash is therefore -$2,055,191.
Cash Flow
| 2014 | -1.39M | -275.37K | 1.75M |
|---|---|---|---|
| 2015 | -842.72K | -133.81K | 839.22K |
| 2016 | -1.31M | 0 | 1.44M |
| 2017 | -3.30M | -7.86K | 8.76M |
| 2018 | -7.70M | -100K | 8.67M |
| 2019 | -8.58M | -43.59K | 8.33M |
| 2020 | -10.77M | -51.33K | 11.87M |
| 2021 | -11.12M | -45K | 13.40M |
| 2022 | -12.76M | -202.57K | 8.39M |
| 2023 | -9.54M | -24.72K | 7.51M |
NDRA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.88M | 9.46M | 7.22M | 6.17M | 6.47M | 5.60M | 144.95K | 19.12K | 156.44K | 78.02K |
Operating activities | ||||||||||
Net income | -10.06M | -13.17M | -11.23M | -11.72M | -13.30M | -9.79M | -5.37M | -2.77M | -2.27M | -2.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 275.45K | 234.25K | 224.41K | 165.24K | 115.01K | 68.31K | 61.48K | 64.93K | 72.22K | 37.24K |
Stock-based compensation expense | 996.43K | 1.19M | 1.44M | 2.10M | 1.39K | 0 | 1.00K | 230.32K | 309.83K | 259.49K |
| Deferred income tax benefit | 996.43K | 1.19M | 1.44M | 2.10M | 1.39K | 0 | 1.00K | 230.32K | 309.83K | 259.49K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | -491.10K | 834.99K | -760.14K | 6.85K | -6.85K | 0 | 0 | 0 |
Inventories | 138.04K | -1.36M | -694.95K | -476.17K | -53.99K | -155.30K | -151.57K | 58.89K | 139.98K | -60.21K |
Accounts payable | -822.25K | 111.57K | 491.10K | -834.99K | 760.14K | -6.18M | 528.29K | 198.13K | 202.58K | 0 |
Cash generated by operating activities | -9.54M | -12.76M | -11.12M | -10.77M | -8.58M | -7.70M | -3.30M | -1.31M | -842.72K | -1.39M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -33.88K | -202.57K | -45K | -51.33K | -43.59K | -100K | -7.86K | 0 | -133.81K | -275.37K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -24.72K | -202.57K | -45K | -51.33K | -43.59K | -100K | -7.86K | 0 | -133.81K | -275.37K |
Financing activities | ||||||||||
Common Stock Issued | 6.48M | 8.39M | 10.61M | 6.78M | 125K | 7.73M | 8.59M | 5K | 839.22K | 1.75M |
Payments for dividends | -840 | -7.79K | 0 | 0 | -4.21M | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -337.08K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -337.08K | 2.49M | -935.3K | 175K | -1.43M | 0 | 0 |
Cash used in financing activities | 7.51M | 8.39M | 13.40M | 11.87M | 8.33M | 8.67M | 8.76M | 1.44M | 839.22K | 1.75M |
Net Change In Cash | -2.05M | -4.57M | 2.23M | 1.05M | -297.16K | 869.49K | 5.45M | 125.82K | -137.31K | 78.41K |
Cash at end of period | 2.83M | 4.88M | 9.46M | 7.22M | 6.17M | 6.47M | 5.60M | 144.95K | 19.12K | 156.44K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |